Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Delivering mitochondrial health
      • Orphan Drugs
    • Relevant publications
  • Mitochondrial Disease
    • Primary mitochondrial disease
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
      • LHON
    • Patients
    • Expanded access policy
  • Research & Development
    • Portfolio
      • KL1333
      • NV354
      • Early programs
    • Clinical trials
      • The FALCON Study
  • AGM 2025
  • Contact
    • Privacy policy

Press releases

  • All
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
All MARRegulatory
27 March, 2024
Regulatory

Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares

The Board of Directors in Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has, in connection with the preferential rights issue announced on 22 February 2024, prepared a prospectus (the ...
Continue reading
8 June, 2022
Regulatory

Abliva publishes prospectus in connection with fully underwritten rights issue and admission to trading of newly issued shares

The Board of Directors in Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has, in connection with the new issues announced on 31 May, 2022, and the conversion of the Company's convertib ...
Continue reading
30 April, 202119 February, 2024
Regulatory

Abliva publishes prospectus and new information contained in the prospectus

Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, tod ...
Continue reading
24 April, 202019 February, 2024
Regulatory

Publication of supplementary prospectus related to NeuroVive’s rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has prepared a supplementary prospectus (the “Supplementary Prospectus”) to the prospectus that was approved and regi ...
Continue reading
3 April, 202019 February, 2024
Regulatory

NeuroVive publishes prospectus and new financial information included in the prospectus in connection with forthcoming rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has in connection with the forthcoming issue of shares with preferential rights for existing shareholders, announced ...
Continue reading
20 April, 2018
Regulatory

NeuroVive publishes supplementary prospectus

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE THE DI ...
Continue reading
9 April, 2018
Regulatory

NeuroVive publishes prospectus in connection with preferential rights issue

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF ...
Continue reading
14 April, 2016
Regulatory

NeuroVive publishes prospectus and announces new publication date of the Q1 interim report

On 28 February 2016, the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive") decided to carry out a new issue of shares and warrants (units) with preferential rights for the company ...
Continue reading
18 May, 2015
Regulatory

NeuroVive announces prospectus regarding admission to trading of new shares

The prospectus regarding the admission to trading of newly issued shares in NeuroVive Pharmaceutical AB (publ) is now available on the company's website www.neurovive.se and in the company's offices, ...
Continue reading
8 January, 2014
Regulatory

NeuroVive Pharmaceutical AB (publ) publishes prospectus

On 20 November 2013, the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive") decided to execute a rights issue. Coincident with this new share issue, NeuroVive has published a prosp ...
Continue reading
  1. Startpage

This is Abliva

  • Delivering mitochondrial health
  • Orphan Drugs
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • The FALCON Study

Contact

Abliva AB (publ)
Medicon Village
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookie policy | Privacy policy

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all